Ultrapotent human neutralizing antibody repertoires against Middle East respiratory syndrome coronavirus from a recovered patient

Journal of Infectious Diseases

Volumn 218, Issue 8, 2018, Pages 1249-1260

  Niu, Peihua ^a   Zhang, Senyan ^b   Zhou, Panpan ^b   Huang, Baoying ^a   Deng, Yao ^a   Qin, Kun ^a   Wang, Pengfei ^b   Wang, Wenling ^a   Wang, Xinquan ^b   Zhou, Jianfang ^a   Zhang, Linqi ^b   Tan, Wenjie ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Crystallographic analysis; Human monoclonal antibody; MERS CoV; Neutralizing antibody repertoires

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS SPIKE PROTEIN; CORONAVIRUS SPIKE GLYCOPROTEIN; VIRUS ANTIBODY;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG ISOLATION; DRUG POTENTIATION; EPITOPE MAPPING; IMMUNOGLOBULIN VARIABLE REGION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; VIRUS NEUTRALIZATION; ADULT; ANTIBODY SPECIFICITY; CASE REPORT; CORONAVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; MALE; MOLECULAR MODEL; PROTEIN CONFORMATION; VIROLOGY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CORONAVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMANS; MALE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MODELS, MOLECULAR; PROTEIN CONFORMATION; SPIKE GLYCOPROTEIN, CORONAVIRUS;

EID: 85055422707     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy311     Document Type: Article

References (42)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-20.
2. Corti D, Zhao J, Pedotti M, et al. Prophylactic and postex-posure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A 2015; 112:10473-8.
3. Wang Y, Liu D, Shi W, et al. Origin and possible genetic recombination of the Middle East respiratory syndrome coronavirus from the first imported case in china: phyloge-netics and coalescence analysis. MBio 2015; 6:e01280-15.
4. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013; 19:1819-23.
5. Ithete NL, Stoffberg S, Corman VM, et al. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis 2013; 19:1697-9.
6. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251-4.
7. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500:227-31.
8. Crowe JE Jr. Principles of broad and potent antiviral human antibodies: insights for vaccine design. Cell Host Microbe 2017; 22:193-206.
9. Magnani DM, Silveira CT, Ricciardi MJ, et al. Potent plasmablast-derived antibodies elicited by the national institutes of health dengue vaccine. J Virol 2017; 91:pii:e00867-17. doi:10.1128/JVI.00867-17
10. Ying T, Du L, Ju TW, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 2014; 88:7796-805.
11. Ying T, Prabakaran P, Du L, et al. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun 2015; 6:8223.
12. Corti D, Passini N, Lanzavecchia A, Zambon M. Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. J Infect Public Health 2016; 9:231-5.
13. Pascal KE, Coleman CM, Mujica AO, et al. Pre- and post-exposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A 2015; 112:8738-43.
14. Johnson RF, Bagci U, Keith L, et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology 2016; 490:49-58.
15. Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014; 6:234ra59.
16. Du L, Zhao G, Yang Y, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 2014; 88:7045-53.
17. Tang XC, Agnihothram SS, Jiao Y, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A 2014; 111:E2018-26.
18. Li Y, Wan Y, Liu P, et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 2015; 25:1237-49.
19. Luke T, Wu H, Zhao J, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med 2016; 8:326ra21.
20. Chen Z, Bao L, Chen C, et al. Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset. J Infect Dis 2017; 215:1807-15.
21. van Doremalen N, Falzarano D, Ying T, et al. Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Res 2017; 143:30-7.
22. Dimitrov DS. Therapeutic antibodies, vaccines and anti-bodyomes. MAbs 2010; 2:347-56.
23. Wang W, Wang H, Deng Y, et al. Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China. Emerg Microbes Infect 2016; 5:e113.
24. Smith K, Garman L, Wrammert J, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 2009; 4:372-84.
25. Wang QS, Yu F, Huang S, et al. The macromolecular crystallography beamline of SSRF. Nucl Sci Tech 2015; 26:12-7.
26. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997; 276:307-26.
27. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007; 40:658-74.
28. Adams PD, Grosse-Kunstleve RW, Hung LW, et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 2002; 58:1948-54.
29. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60:2126-32.
30. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993; 26:283-91.
31. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70:440-6.
32. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
33. Prabakaran P, Zhu Z, Chen W, et al. Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front Microbiol 2012; 3:277.
34. Ohshima N, Iba Y, Kubota-Koketsu R, Asano Y, Okuno Y, Kurosawa Y. Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. J Virol 2011; 85:11048-57.
35. Chan CH, Hadlock KG, Foung SK, Levy S. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 2001; 97:1023-6.
36. Yu F, Song H, Wu Y, et al. A potent germline-like human monoclonal antibody targets a pH-sensitive epitope on H7N9 influenza hemagglutinin. Cell Host Microbe 2017; 22:471-83 e5.
37. Zhou T, Zhu J, Wu X, et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013; 39:245-58.
38. Cotten M, Watson SJ, Kellam P, et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet 2013; 382:1993-2002.
39. Li W, Zhang C, Sui J, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005; 24:1634-43.
40. Bermingham A, Chand MA, Brown CS, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 2012; 17:20290.
41. Tang XC, Marasco WA. Human neutralizing antibodies against MERS coronavirus: implications for future immu-notherapy. Immunotherapy 2015; 7:591-4.
42. Wang L, Shi W, Joyce MG, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 2015; 6:7712.